Hiroyuki Izutsu

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 6

Top Topics

Rheumatoid Arthritis

Top Venues

Annals of the rheumatic diseases

Modern rheumatology

Arthritis research & therapy

Expert opinion on pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato, Yuichiro Kaneko, Musashi Fukuda, Hiroyuki Izutsu, Mitsuhiro Rokuda
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years. Modern rheumatology 32 (4) (2022)
Yoshiya Tanaka, Tsutomu Takeuchi, Hiroyuki Izutsu, Yuichiro Kaneko, Daisuke Kato, Musashi Fukuda, Mitsuhiro Rokuda, Neil M Schultz
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. Arthritis research & therapy 23 (1) (2021)
Tsutomu Takeuchi, Yoshiya Tanaka, Mitsuhiro Rokuda, Hiroyuki Izutsu, Yuichiro Kaneko, Musashi Fukuda, Daisuke Kato
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. Modern rheumatology 31 (3) (2020)
Yoshiya Tanaka, Hiroyuki Izutsu
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. Expert opinion on pharmacotherapy 21 (9) (2020)
Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Manabu Iwasaki, Kou Katayama, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Teruaki Shiomi, Emi Yamada, Désirée Mfm van der Heijde
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Annals of the rheumatic diseases 78 (10) (2019)
Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, Atsushi Kawakami, Manabu Iwasaki, Yeong Wook Song, Yi-Hsing Chen, James Cheng-Chung Wei, Sang-Heon Lee, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Rio Akazawa, Teruaki Shiomi, Emi Yamada
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Annals of the rheumatic diseases 78 (10) (2019)